复宏汉霖(02696)：HLX701联合西妥昔单抗和化疗治疗晚期结直肠癌的1b/2期临床试验申请获NMPA批准

智通财经01-20

智通财经APP讯，复宏汉霖(02696)公布，近日，HLX701(重组人SIRPα-IgG4 Fc 融合蛋白注射液)(HLX701)联合西妥昔单抗和化疗治疗晚期结直肠癌的 1b/2期临床试验申请(IND)获国家药品监督管理局(NMPA)批准。HLX701是公司自FBD Biologics Limited许可引进的SIRPα-Fc融合蛋白，拟用于多种晚期实体瘤的治疗，目前该产品的多项1/2期临床试验...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2604195516?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-20 17:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604195516","market":"fut","top_or_hot":-1,"title":"复宏汉霖(02696)：HLX701联合西妥昔单抗和化疗治疗晚期结直肠癌的1b/2期临床试验申请获NMPA批准","media":"智通财经","content":"<div>\n<p>智通财经APP讯，复宏汉霖(02696)公布，近日，HLX701(重组人SIRPα-IgG4 Fc 融合蛋白注射液)(HLX701)联合西妥昔单抗和化疗治疗晚期结直肠癌的 1b/2期临床试验申请(IND)获国家药品监督管理局(NMPA)批准。HLX701是公司自FBD Biologics Limited许可引进的SIRPα-Fc融合蛋白，拟用于多种晚期实体瘤的治疗，目前该产品的多项1/2期临床试验...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1395069.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复宏汉霖(02696)：HLX701联合西妥昔单抗和化疗治疗晚期结直肠癌的1b/2期临床试验申请获NMPA批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复宏汉霖(02696)：HLX701联合西妥昔单抗和化疗治疗晚期结直肠癌的1b/2期临床试验申请获NMPA批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-20 17:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1395069.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，复宏汉霖(02696)公布，近日，HLX701(重组人SIRPα-IgG4 Fc 融合蛋白注射液)(HLX701)联合西妥昔单抗和化疗治疗晚期结直肠癌的 1b/2期临床试验申请(IND)获国家药品监督管理局(NMPA)批准。HLX701是公司自FBD Biologics Limited许可引进的SIRPα-Fc融合蛋白，拟用于多种晚期实体瘤的治疗，目前该产品的多项1/2期临床试验...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1395069.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000320264.USD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1395069.html","article_id":"2604195516","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2604195516","pubTimestamp":1768899619,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，复宏汉霖 公布，近日，HLX701联合西妥昔单抗和化疗治疗晚期结直肠癌的 1b/2期临床试验申请获国家药品监督管理局批准。HLX701是公司自FBD Biologics Limited许可引进的SIRPα-Fc融合蛋白，拟用于多种晚期实体瘤的治疗，目前该产品的多项1/2期临床试验正于全球范围内开展中。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","02696":"复宏汉霖","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK1161":"生物科技","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC"},"translate_title":"Henlius (02696): Phase 1b/2 clinical trial application of HLX701 combined with cetuximab and chemotherapy for the treatment of advanced colorectal cancer was approved by NMPA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1.5},"content_text":"智通财经APP讯，复宏汉霖(02696)公布，近日，HLX701(重组人SIRPα-IgG4 Fc 融合蛋白注射液)(HLX701)联合西妥昔单抗和化疗治疗晚期结直肠癌的 1b/2期临床试验申请(IND)获国家药品监督管理局(NMPA)批准。HLX701是公司自FBD Biologics Limited许可引进的SIRPα-Fc融合蛋白，拟用于多种晚期实体瘤的治疗，目前该产品的多项1/2期临床试验正于全球范围内开展中。根据许可安排，公司获得于中国(除中国台湾地区)及东南亚、中东和北非的特定国家开发、生产及商业化HLX701的独家许可权利。 HLX701是一种工程改构的人类SIRPα免疫球蛋白(IgV)结构域与人免疫球蛋白G4(IgG4)片段可结晶(Fc)区域蛋白结合的融合蛋白。通过与肿瘤细胞上的 CD47结合，HLX701可有效阻断抑制性CD47抗吞噬信号，促进巨噬细胞对肿瘤细胞的吞噬作用及增强抗肿瘤活性。临床前研究显示HLX701可与化疗药物、免疫检查点抑制剂、表皮生长因子受体抑制剂及抗血管生成药物等多种药物产生协同效应，提示HLX701与标准治疗方案联用有望协同增强先天性与适应性免疫应答。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604195516","isCrawlerRequest":true}